The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
646
Combination Tablet of Treximet
placebo to match
Score on a migraine pain scale for multiple migraine attacks
Time frame: 2 to 24 hours
Within patient consistency of response, freedom from all migraine pain and symptoms, satisfaction, presence or absence of neck pain/discomfort, sinus pain/pressure, recurrence of head pain, safety and tolerability
Time frame: 2 to 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Irvine, California, United States
GSK Investigational Site
Newport Beach, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Santa Monica, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
Westlake Village, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
...and 40 more locations